Samina Khan

Net worth: 7 M $ as of 30/09/2023

59 year

Consumer Services

Health Technology

Profile

Presently, Samina Khan holds the position of Chief Medical Officer & Senior Vice President of Reata Pharmaceuticals, Inc. Dr. Khan previously was Vice President-Cardio-Renal Programs at Quark Pharmaceuticals, Inc.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
REATA PHARMACEUTICALS, INC. CLASS A 0.12%	16/05/2023	39,491 ( 0.12% )	7 M $	30/09/2023

Former positions of Samina Khan

Companies	Position	End
REATA PHARMACEUTICALS, INC.	Chief Tech/Sci/R&D Officer	26/09/2023
Quark Pharmaceuticals, Inc. Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.	Corporate Officer/Principal	01/04/2017
Tufts University School of Medicine	Corporate Officer/Principal	-

See the detail of Samina Khan's experience

Training of Samina Khan

Brandeis University	Masters Business Admin
Harvard Medical School	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Samina Khan's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Reata Pharmaceuticals, Inc. Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX.	Health Technology
Quark Pharmaceuticals, Inc. Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.	Health Technology